News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bayer AG (BAY.F)'s Nexavar Not Recommended by National Institute for Clinical Excellence (NICE) for Liver Cancer



5/7/2009 7:05:52 AM

Bookmark and Share Reuters -- Britain's healthcare cost-effectiveness watchdog said on Thursday it had recommended that Bayer AG's new drug Nexavar should not be given on the state health service to patients with liver cancer.

Read at Reuters


comments powered by Disqus
Reuters
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES